Home/Alpha Fusion/Takanori Nakano, Ph.D.
TN

Takanori Nakano, Ph.D.

Co-founder, Board Director

Alpha Fusion

Therapeutic Areas

Alpha Fusion Pipeline

DrugIndicationPhase
af-001 (TAH-1005)Thyroid Cancer (Radioiodine-Refractory)Phase 1
af-001Thyroid Cancer (Radioiodine-Naïve)Phase 1
af-002 (PSW-1025)Prostate Cancer (Refractory)IND-enabling
af-003Pan-CancerIND-enabling
Tanabe-Veneno ProgramUndisclosedExploratory
In-house ProgramUndisclosedExploratory